Table 1 Top pathways and associated networks identified by pathway analysis for the hippocampus following olanzapine treatment
From: The effects of olanzapine on genome-wide DNA methylation in the hippocampus and cerebellum
(a) Top canonical pathways (Genes with increased methylation) | P- value | No of moleculesa |
|---|---|---|
Dopamine-DARPP32 feedback in cAMP signalling | 1.65 × 10–3 | 20/157 (0.127) |
CD27 signalling in lymphocytes | 2.42 × 10–4 | 11/54 (0.204) |
Oestrogen-mediated S-phase entry | 2.56 × 10–3 | 6/26 (0.231) |
Role of JAK2 in hormone-like cytokine signalling | 3.38 × 10–3 | 7/34 (0.206) |
Associated network functions | Â | Â |
Metabolic disease, endocrine system and developmental disorders | 35 | |
Cell cycle, cellular growth and proliferation, cell death | 24 | |
Molecular transport, neurological disease, cell-to-cell signalling | 10 | |
(b) Top canonical pathways (Genes with decreased methylation) | P- value | No of molecules |
CDC42 signalling | 2.52 × 10–3 | 11/131 (0.084) |
Prostanoid biosynthesis | 2.55 × 10–3 | 3/9 (0.333) |
Calcium signalling | 5.92 × 10–3 | 12/178 (0.067) |
D-myo-inositol (1,3,4,5,6)-tetrakisphosphatebiosynthesis | 6.18 × 10–3 | 8/48 (0.167) |
Associated network functions | Â | |
Developmental disorder, cell death and survival, cellular development | 12 | |
Molecular transport, nervous system development and function | 10 | |
Carbohydrate metabolism, cell morphology, lipid metabolism | 9 | |
Cellular development, skeletal, muscular and cardiovascular system development and function | 8 | |